Pfizer phase 3 results for nonsegmental vitiligo treatment

 Pfizer has announced positive topline results from two phase 3 trials evaluating the efficacy and safety of Litfulo once daily in patients with both active and stable nonsegmental vitiligo (NSV) and who had a broad range of disease severity.

The TRANQUILLO study included patients aged 12 years and older, while TRANQUILLO 2 enrolled adults only. Across the studies, both the 50 and 100 milligram doses of Litfulo delivered significant, clinically meaningful improvements over placebo on co-primary endpoints for the facial and total body Vitiligo Area Scoring Index, or VASI.

Based on these results, Pfizer intends to submit global regulatory filings for Litfulo as a potential new oral systemic therapy for NSV for adults.

“Litfulo has a unique mechanism of action targeting TEC family kinases and JAK3, giving rise to its distinct clinical profile,” said Michael Vincent, Chief Inflammation & Immunology Officer at Pfizer. “These findings give us confidence that, if approved, Litfulo could become a new oral systemic treatment option for adults living with NSV, significantly improving and potentially maintaining facial and total body repigmentation.”

https://pmlive.com/pharma_news/pfizer-announces-phase-3-results-for-nonsegmental-vitiligo-treatment/